Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, bone lesions, Macrophage-Colony Stimulating Factor
Brief summary
The Primary objective of this study is to compare serum levels of Macrophage-Colony Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a population of patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and in a control population.
Interventions
BIOLOGICALblood samples
BIOLOGICALBone marow samples
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
For the multiple myeloma group * confirmed diagnosis of de novo multiple myeloma according to the International Myeloma Working Group criteria * bisphosphonate therapy for more than 60 days, * signature of the informed consent form, * patients over the age of 18 years. For the monoclonal gammopathy of undetermined significance (MGUS) group * confirmed diagnosis of MGUS according to the International Myeloma Working Group criteria * signature of the informed consent form, * patients over the age of 18 years. For the healthy control group * signature of the informed consent form, * subjects over the age of 18 years.
Exclusion criteria
* patients with thyroid or parathyroid disease, * osteomalacia, rheumatoid arthritis, Paget's disease, osteoporosis, * bisphosphonate therapy for less than 60 days, * absence of informed consent, * patients under the age of 18 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Macrophage-Colony Stimulating Factor (M-CSF) levels | Day 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumour osteolysis | Day 1 | determined by the presence of osteolytic lesions, osteopenia or pathological fractures, presence of bone pain |
Countries
France
Outcome results
None listed